Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Ishii, Ryotaro ^a   Tokuda, Takahiko ^a   Tatebe, Harutsugu ^a   Ohmichi, Takuma ^a   Kasai, Takashi ^a   Nakagawa, Masanori ^b   Mizuno, Toshiki ^a   El Agnaf, Omar M A ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c QATAR FOUNDATION   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN ANTIBODY; BIOLOGICAL MARKER;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; HEMOLYSIS; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; PROTEIN BLOOD LEVEL; BLOOD; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANTIBODIES, HETEROPHILE; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84927588680     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123162     Document Type: Article

References (39)

1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840. PMID: 9278044
2. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun. 2006; 349: 162-166. PMID: 16930553
3. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008; 213: 315-325. doi: 10.1016/j.expneurol.2008.06.004 PMID: 18625222
4. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010; 75: 1766-1772. doi: 10.1212/WNL.0b013e3181fd613b PMID: 20962290
5. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133: 713-726. doi: 10.1093/brain/awq008 PMID: 20157014
6. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011; 10: 230-240. doi: 10.1016/S1474-4422(11)70014-X PMID: 21317042
7. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, et al. Cerebrospinal fluid Tau/ α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord. 2011; 26: 1428-1435. doi: 10.1002/mds.23670 PMID: 21469206
8. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord. 2012; 26: 213-216. doi: 10.1097/WAD.0b013e31823899cc PMID: 22037599
9. Wennstrom M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis. 2012; 29: 125-132. doi: 10.3233/JAD-2012-111655 PMID: 22207004
10. Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-Doring F, Ebentheuer J, et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett. 2013; 532: 44-48. doi: 10.1016/j.neulet.2012.11.004 PMID: 23149132
11. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett. 2009; 450: 332-335. doi: 10.1016/j.neulet.2008.11.015 PMID: 19022350
12. Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, et al. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis. 2010; 22: 87-95. doi: 10.3233/JAD-2010-100186 PMID: 20847452
13. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol. 2011; 7: 215-222. doi: 10.3988/jcn.2011.7.4.215 PMID: 22259618
14. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012; 33: 430.e1-430.e3. doi: 10.1016/j.neurobiolaging.2010.12.010 PMID: 21272962
15. Foulds PG, Yokota O, Thurston A, Davidson Y, Ahmed Z, Holton J, et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis. 2012; 45: 188-195. doi: 10.1016/j.nbd.2011.08.003 PMID: 21856424
16. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999; 45: 942-956. PMID: 10388468
17. Levinson SS, Miller JJ. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta 2002; 325: 1-15. PMID: 12367762
18. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab. 2003; 88: 3069-3074. PMID: 12843145
19. Sehlin D, Sollvander S, Paulie S, Brundin R, Ingelsson M, Lannfelt L, et al. Interference from heterophilic antibodies in amyloid-β oligomer ELISAs. J Alzheimers Dis. 2010; 21: 1295-1301. PMID: 21504116
20. Bartels EM, Ribel-Madsen S. Cytokine measurements and possible interference from heterophilic antibodies - problems and solutions experienced with rheumatoid factor. Methods 2013; 61: 18-22. doi: 10.1016/j.ymeth.2012.12.015 PMID: 23306035
21. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006; 20: 419-425. PMID: 16507759
22. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm. 2006; 113: 1435-1439. PMID: 16465458
23. Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, Masters CL, et al. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol. 2007; 204: 583-588. PMID: 17258710
24. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010; 480: 78-82. doi: 10.1016/j.neulet.2010.06.009 PMID: 20540987
25. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M Vives F. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord. 2010; 25: 489-493. doi: 10.1002/mds.22928 PMID: 20063406
26. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, et al. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 2011; 25: 4127-4137. doi: 10.1096/fj.10-179192 PMID: 21865317
27. Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, Maetzler W. Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. Dement Geriatr Cogn Disord. 2011; 31: 413-416. doi: 10.1159/000329763 PMID: 21757905
28. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008; 5: 55-59. doi: 10.1159/000112832 PMID: 18182779
29. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci. 1996; 141: 65-68. PMID: 8880695
30. Woulfe JM, Duke R, Middeldorp JM, Stevens S, Vervoort M, Hashimoto M, et al. Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology 2002; 58: 1435-1436. PMID: 12011302
31. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G Papadimitriou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem. 2007; 101: 749-756. PMID: 17448146
32. Smith LM, Schiess MC, Coffey MP, Klaver AC, Loeffler DA. α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS One 2012; 7: e52285. doi: 10.1371/journal.pone.0052285 PMID: 23284971
33. Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, Poewe W, et al. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 2013; 80: 169-175. doi: 10.1212/WNL.0b013e31827b90d1 PMID: 23255825
34. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013; 70: 1277-1287. PMID: 23979011
35. Kasai T, Tokuda T, Ishii R, Ishigami N, Tsuboi Y, Nakagawa M, et al. Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol. 2014; 261: 1203-1209. doi: 10.1007/s00415-014-7334-7 PMID: 24737170
36. Fumimura Y, Ikemura M, Saito Y, Sengoku R, Kanemaru K, Sawabe M, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol. 2007; 66: 354-362. PMID: 17483692
37. Mitsui J, Saito Y, Momose T, Shimizu J, Arai N, Shibahara J, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci. 2006; 243: 101-104. PMID: 16442563
38. Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol. 2013; 260: 1332-1338. doi: 10.1007/s00415-012-6801-2 PMID: 23263478
39. Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, Kanemaru K, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol. 2008; 67: 945-953. doi: 10.1097/NEN.0b013e318186de48 PMID: 18800013